Ribozyme-mediated specific gene replacement of the α1-antitrypsin gene in human hepatoma cells

Iwata Ozaki, Mark A Zern, Shuling Liu, Dan Lan Wei, Roger J. Pomerantz, Lingxun Duan

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background/Aims: Some of the mutant forms of cellular proteins not only lose their function, but also cause diseases by their toxic effects. One of the challenging tasks in the field of gene therapy will be 'gene replacement' accomplished by inhibiting mutant gene expression and providing normal function of the same gene, simultaneously. Although lung involvement in α1- antrypsin (α1-AT) deficiency is caused by the lack of α1-AT function, the liver involvement is due to the accumulation of the mutated α1-AT protein. Therefore, one possible approach to prevent and treat the disease manifestations of α1-AT deficiency is to inhibit the expression of the mutated gene and replace it with normally functioning α1-AT protein in the liver. Methods: For the inhibition of α1-AT gene expression, panels of α1- AT-specific hammerhead ribozymes designed to target different GUC sites in the α1-AT mRNA were evaluated in a human hepatoma cell-line, transduced with retroviral vectors which express ribozymes under the control of a human tRNA promoter. A bi-functional vector was also constructed, which contained a functional α1-AT ribozyme and was combined with a modified α1-AT gene, whose product was engineered to be resistant to the specific α1-AT ribozyme. This construct was transduced into target hepatoma cells. Results: The transduced hepatoma cells showed the effective expression of modified α1- AT, under the conditions where the endogenous α1-AT gene expression was inhibited. Conclusion: This ribozyme-mediated, specific gene replacement is a first step in the gene therapy of α1-AT deficiency.

Original languageEnglish (US)
Pages (from-to)53-60
Number of pages8
JournalJournal of Hepatology
Volume31
Issue number1
DOIs
StatePublished - Jul 1999
Externally publishedYes

Fingerprint

Catalytic RNA
Hepatocellular Carcinoma
Gene Expression
Genetic Therapy
Genes
Proteins
Poisons
Liver
Transfer RNA
Cell Line
Lung
Messenger RNA

Keywords

  • α1-AT deficiency
  • Gene therapy
  • Ribozyme

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Ribozyme-mediated specific gene replacement of the α1-antitrypsin gene in human hepatoma cells. / Ozaki, Iwata; Zern, Mark A; Liu, Shuling; Wei, Dan Lan; Pomerantz, Roger J.; Duan, Lingxun.

In: Journal of Hepatology, Vol. 31, No. 1, 07.1999, p. 53-60.

Research output: Contribution to journalArticle

Ozaki, Iwata ; Zern, Mark A ; Liu, Shuling ; Wei, Dan Lan ; Pomerantz, Roger J. ; Duan, Lingxun. / Ribozyme-mediated specific gene replacement of the α1-antitrypsin gene in human hepatoma cells. In: Journal of Hepatology. 1999 ; Vol. 31, No. 1. pp. 53-60.
@article{ec90f6de22054591bdbcec4954b5c705,
title = "Ribozyme-mediated specific gene replacement of the α1-antitrypsin gene in human hepatoma cells",
abstract = "Background/Aims: Some of the mutant forms of cellular proteins not only lose their function, but also cause diseases by their toxic effects. One of the challenging tasks in the field of gene therapy will be 'gene replacement' accomplished by inhibiting mutant gene expression and providing normal function of the same gene, simultaneously. Although lung involvement in α1- antrypsin (α1-AT) deficiency is caused by the lack of α1-AT function, the liver involvement is due to the accumulation of the mutated α1-AT protein. Therefore, one possible approach to prevent and treat the disease manifestations of α1-AT deficiency is to inhibit the expression of the mutated gene and replace it with normally functioning α1-AT protein in the liver. Methods: For the inhibition of α1-AT gene expression, panels of α1- AT-specific hammerhead ribozymes designed to target different GUC sites in the α1-AT mRNA were evaluated in a human hepatoma cell-line, transduced with retroviral vectors which express ribozymes under the control of a human tRNA promoter. A bi-functional vector was also constructed, which contained a functional α1-AT ribozyme and was combined with a modified α1-AT gene, whose product was engineered to be resistant to the specific α1-AT ribozyme. This construct was transduced into target hepatoma cells. Results: The transduced hepatoma cells showed the effective expression of modified α1- AT, under the conditions where the endogenous α1-AT gene expression was inhibited. Conclusion: This ribozyme-mediated, specific gene replacement is a first step in the gene therapy of α1-AT deficiency.",
keywords = "α1-AT deficiency, Gene therapy, Ribozyme",
author = "Iwata Ozaki and Zern, {Mark A} and Shuling Liu and Wei, {Dan Lan} and Pomerantz, {Roger J.} and Lingxun Duan",
year = "1999",
month = "7",
doi = "10.1016/S0168-8278(99)80163-9",
language = "English (US)",
volume = "31",
pages = "53--60",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Ribozyme-mediated specific gene replacement of the α1-antitrypsin gene in human hepatoma cells

AU - Ozaki, Iwata

AU - Zern, Mark A

AU - Liu, Shuling

AU - Wei, Dan Lan

AU - Pomerantz, Roger J.

AU - Duan, Lingxun

PY - 1999/7

Y1 - 1999/7

N2 - Background/Aims: Some of the mutant forms of cellular proteins not only lose their function, but also cause diseases by their toxic effects. One of the challenging tasks in the field of gene therapy will be 'gene replacement' accomplished by inhibiting mutant gene expression and providing normal function of the same gene, simultaneously. Although lung involvement in α1- antrypsin (α1-AT) deficiency is caused by the lack of α1-AT function, the liver involvement is due to the accumulation of the mutated α1-AT protein. Therefore, one possible approach to prevent and treat the disease manifestations of α1-AT deficiency is to inhibit the expression of the mutated gene and replace it with normally functioning α1-AT protein in the liver. Methods: For the inhibition of α1-AT gene expression, panels of α1- AT-specific hammerhead ribozymes designed to target different GUC sites in the α1-AT mRNA were evaluated in a human hepatoma cell-line, transduced with retroviral vectors which express ribozymes under the control of a human tRNA promoter. A bi-functional vector was also constructed, which contained a functional α1-AT ribozyme and was combined with a modified α1-AT gene, whose product was engineered to be resistant to the specific α1-AT ribozyme. This construct was transduced into target hepatoma cells. Results: The transduced hepatoma cells showed the effective expression of modified α1- AT, under the conditions where the endogenous α1-AT gene expression was inhibited. Conclusion: This ribozyme-mediated, specific gene replacement is a first step in the gene therapy of α1-AT deficiency.

AB - Background/Aims: Some of the mutant forms of cellular proteins not only lose their function, but also cause diseases by their toxic effects. One of the challenging tasks in the field of gene therapy will be 'gene replacement' accomplished by inhibiting mutant gene expression and providing normal function of the same gene, simultaneously. Although lung involvement in α1- antrypsin (α1-AT) deficiency is caused by the lack of α1-AT function, the liver involvement is due to the accumulation of the mutated α1-AT protein. Therefore, one possible approach to prevent and treat the disease manifestations of α1-AT deficiency is to inhibit the expression of the mutated gene and replace it with normally functioning α1-AT protein in the liver. Methods: For the inhibition of α1-AT gene expression, panels of α1- AT-specific hammerhead ribozymes designed to target different GUC sites in the α1-AT mRNA were evaluated in a human hepatoma cell-line, transduced with retroviral vectors which express ribozymes under the control of a human tRNA promoter. A bi-functional vector was also constructed, which contained a functional α1-AT ribozyme and was combined with a modified α1-AT gene, whose product was engineered to be resistant to the specific α1-AT ribozyme. This construct was transduced into target hepatoma cells. Results: The transduced hepatoma cells showed the effective expression of modified α1- AT, under the conditions where the endogenous α1-AT gene expression was inhibited. Conclusion: This ribozyme-mediated, specific gene replacement is a first step in the gene therapy of α1-AT deficiency.

KW - α1-AT deficiency

KW - Gene therapy

KW - Ribozyme

UR - http://www.scopus.com/inward/record.url?scp=0032992064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032992064&partnerID=8YFLogxK

U2 - 10.1016/S0168-8278(99)80163-9

DO - 10.1016/S0168-8278(99)80163-9

M3 - Article

C2 - 10424283

AN - SCOPUS:0032992064

VL - 31

SP - 53

EP - 60

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 1

ER -